ClinicalTrials.gg
RecruitingNCT05756582CROSSWORDUpdated Feb 13, 2024

Prevalence of Latent Tuberculosis Infection in Health-care Workers and Students

An observational study in Tuberculosis, Tuberculosis, Pulmonary and Tuberculosis Infection, sponsored by Eleonora Nucera. Recruiting at 1 site in Italy. Open to participants aged 18 Years to 72 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-02-13.

Sponsored by Eleonora Nucera · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2026, 4 months ago, but the record still lists the study as recruiting.
  • Started Nov 2021; still recruiting 5 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
2,040
Ages
18 Years to 72 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 17 studies in Tuberculosis with a site in Italy — 5 open to participants now, 6 under way, none of them phase 3. Tuberculosis · Italy.

Planned enrollment
3rd of 12
2,040 · median 580
Started
2021
with 2 others
Observational
12 of 17
5 open now
Registered
12th of 17
by date
Lead sponsor
1 of 17
Eleonora Nucera

Among the 17 studies in Tuberculosis with a site in Italy, this one is the 3rd largest by planned enrollment of the 12 observational ones that give a count, is one of 3 that started in 2021, is one of 12 observational ones, and was the 12th registered.

Tuberculosis

1,173 studies on the registry are indexed under Tuberculosis; 177 are open to participants now.

Browse Tuberculosis studies →

Open to participants now

5 of the 17 studies in Tuberculosis with a site in Italy are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 112 Tuberculosis studies recruiting now, 65 (58%) set no upper age limit and 37 (33%) stop at 75 or younger; 49 take children under 18; 31 take healthy volunteers.

This study: 18 Years to 72 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Tuberculosis with a site in Italy, or all of them as a file.
02

Study summary

This study is a cross-sectional study that examines the prevalence of Latent Tuberculosis Infection [LTBI], defined as individuals infected with Mycobacterium tuberculosis with no clinical evidence of disease, and the possible risk factors of LTBI in a large cohort of health care workers (HCWs) and students.

Read the detailed description

Mycobacterium tuberculosis may develop symptoms and signs of disease or may have no clinical evidence of disease (latent tuberculosis infection [LTBI]). TB disease remains one of the major causes of morbidity and mortality in the world.

A survey to assess the prevalence of the individuals with a LTBI and evaluate the potential main risk-factors will be performed on both HCWs and students attending the hospital wards, trained at Fondazione Policlinico Universitario A. Gemelli IRCCS in Rome.

This study is a cross-sectional study that examines the prevalence of Latent Tuberculosis Infection [LTBI], defined as individuals infected with Mycobacterium tuberculosis (MT) with no clinical evidence of disease, and the possible risk factors of LTBI in a large cohort of health care workers (HCWs) and students.

The study will involve all HCWs of Fondazione Policlinico Universitario A. Gemelli IRCCS in Rome - a tertiary reference hospital with over 1,500 beds - and all students of all three-year and single-cycle degree courses, master's degree courses, graduate schools of the faculty of Medicine and Surgery of the Catholic University of Sacred Heart in Rome, trained at the Fondazione Policlinico Universitario A. Gemelli IRCCS.

All enrolled participants, who will agree to participate to the study and answer the questionnaire, will respond a cross-sectional questionnaire survey through dedicated tablet. The survey will contain a brief explanation of the study aims and an invitation to respond to a 9 items multiple choice questionnaire.

03

Conditions studied

  • Tuberculosis
  • Tuberculosis, Pulmonary
  • Tuberculosis Infection
  • Latent Tuberculosis
  • Health Care Associated Infection

Keywords

  • latent tuberculosis infection
  • health-care workers
  • students
  • survey
04

Who can participate

Ages eligible
18 Years to 72 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

The study will involve all HCWs of Fondazione Policlinico Universitario A. Gemelli IRCCS in Rome - a tertiary reference hospital with over 1,500 beds - and all students of all three-year and single-cycle degree courses, master's degree courses, graduate schools of the faculty of Medicine and Surgery of the Catholic University of Sacred Heart in Rome, trained at the Fondazione Policlinico Universitario A. Gemelli IRCCS.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • all health-care workers of Fondazione Policlinico Universitario A. Gemelli IRCCS in Rome,
  • all students of all three-year and single-cycle degree courses, master's degree courses, graduate schools of the faculty of Medicine and Surgery of the Catholic University of Sacred Heart in Rome, trained at the Fondazione Policlinico Universitario A. Gemelli IRCCS,
  • written .

Exclusion criteria

Exclusion Criteria:

  • denied .
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
2,040 participants (estimated)
Patient registry
No

Groups and cohorts

  • Health-care workers and students

    The study will involve all health-care workers of Fondazione Policlinico Universitario A. Gemelli IRCCS in Rome - a tertiary reference hospital with over 1,500 beds - and all students of all three-year and single-cycle degree courses, master's degree courses, graduate schools of the faculty of Medicine and Surgery of the Catholic University of Sacred Heart in Rome, trained at the Fondazione Policlinico Universitario A. Gemelli IRCCS.

    Diagnostic Test: Prevalence of Latent Tuberculosis Infection

Interventions

  • Diagnostic testPrevalence of Latent Tuberculosis Infection

    The prevalence of Latent Tuberculosis Infection \[LTBI\] is defined as 1) tuberculin conversion after a documented negative-baseline tuberculin skin test (TST), 2) positive result of the QuantiFERON-TB Gold (QFT) test performed \[higher response than the cut-off value of 0.35 IU / ml of INF-γ was detected in at least one test tube (TB1 or TB2)\], 3) chest imaging excluding pleural and/or pulmonary lesions suggestive of active tuberculosis and 4) final medical evaluation done by a Specialist in Infectious Diseases which excluded active disease. All four criteria must be met.

06

What researchers measure

Primary outcomes

  1. The prevalence of Latent Tuberculosis Infection

    The prevalence of Latent Tuberculosis Infection \[LTBI\] defined as 1) tuberculin conversion after a documented negative-baseline tuberculin skin test (TST), 2) positive result of the QuantiFERON-TB Gold (QFT) test performed \[higher response than the cut-off value of 0.35 IU / ml of INF-γ was detected in at least one test tube (TB1 or TB2)\], 3) chest imaging excluding pleural and/or pulmonary lesions suggestive of active tuberculosis and 4) final medical evaluation done by a Specialist in Infectious Diseases which excluded active disease. All four criteria must be met.

    Time frame: At enrollment.

Secondary outcomes

  1. Age

    Age as possible risk factor of Latent Tuberculosis Infection.

    Time frame: At enrollment.

  2. Sex

    Sex as possible risk factor of Latent Tuberculosis Infection.

    Time frame: At enrollment.

  3. Vaccination history

    Bacillus Calmette-Guérin (BCG) vaccination history as possible risk factor of Latent Tuberculosis Infection.

    Time frame: At enrollment.

  4. Previous work or stay in other at risk countries

    Previous work or stay in other countries with high TB rates including Armenia, Azerbaijan, Belarus, Bulgaria, Estonia, Georgia, Kazakhstan, Kyrgyzstan, Latvia, Lithuania, Moldova, Romania, Russia, Tajikistan, Turkey, Turkmenistan, Ukraine and Uzbekistan; as possible risk factor of Latent Tuberculosis Infection.

    Time frame: At enrollment.

  5. Recent exposure

    Known recent (within 6 months) exposure to TB-infected patient; as possible risk factor of Latent Tuberculosis Infection.

    Time frame: At enrollment.

  6. Smoking

    Current smoking as possible risk factor of Latent Tuberculosis Infection.

    Time frame: At enrollment.

  7. Co-morbidities / medical history

    Co-morbidities / medical history \[HIV, diabetes, silicosis, chronic kidney disease, solid organ transplant, malignant hematologic malignancies or undergoing chemotherapy, gastrectomy or fasting bypass, biological drugs\]; as possible risk factor of Latent Tuberculosis Infection.

    Time frame: At enrollment.

  8. QuantiFERON-TB

    Median QuantiFERON-TB Gold In-Tube level (TB Ag-Nil) as possible risk factor of Latent Tuberculosis Infection.

    Time frame: At enrollment.

  9. Occupation

    Occupation \[doctor, nurse, laboratory technicians, paramedical personnel, "preclinical" students with no contact with patients inside the hospital, and "clinical" students attending various medical, laboratory, and surgical departments of the hospital, including the infectious disease wards\] as possible risk factor of Latent Tuberculosis Infection.

    Time frame: At enrollment.

  10. Working / training Unit

    Working / training Unit as possible risk factor of Latent Tuberculosis Infection.

    Time frame: At enrollment.

  11. Years working as HCW

    Years working as HCW as possible risk factor of Latent Tuberculosis Infection.

    Time frame: At enrollment.

07

Study locations

1 of 1 sites recruiting
  • UOSD Allergologia e Immunologia Clinica, Fondazione Policlinico Universitario A. Gemelli IRCCS
    Roma, 00168, Italy
    Recruiting
    • Angela Rizzi, MD, PhD · Contactangela.rizzi@policlinicogemelli.it · +390630154965
    • Raffaella Chini, MD · Contactraffaella.chini@guest.policlinicogemelli.it · +390630154965
    • Vincenzina Anzelmo, Prof., MD · Sub investigator
    • Raffaella Chini, MD · Sub investigator
    • Giancarlo Scoppettuolo, MD · Sub investigator
    • Luca Boldrini, MD · Sub investigator
    • Gabriele Rumi, MD · Sub investigator
    • Carlotta Masciocchi, Eng. · Sub investigator
    • Michela Sali, MD · Sub investigator
    • Riccardo Inchingolo, MD, PhD · Sub investigator
    • Chiara La Face, MD · Sub investigator
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2021 (actual). Primary completion is estimated for Jun 2026, 55 months after the start.

Of 123 non-industry observational studies under Tuberculosis, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 76. This study's planned 55 months is above that.

Counting every sponsor, half of 135 studies reached it within 36 months; a quarter within 21 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 19, 2023
First posted
Mar 6, 2023
StartActual
Nov 17, 2021
Primary completionEst.
Jun 30, 2026
CompletionEst.
Dec 15, 2026
Last update
Feb 13, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 13, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05756582
Lead sponsor
Eleonora Nucera
Responsible party
Eleonora Nucera (Head of Allergy Unit, Catholic University of the Sacred Heart) — Sponsor-investigator
First posted
Mar 6, 2023
Start date
Nov 17, 2021
Primary completion
Jun 30, 2026 (estimated)
Completion
Dec 15, 2026 (estimated)
Last update
Feb 13, 2024

Study contacts

Angela Rizzi, MD, PhD
Contact
angela.rizzi@policlinicogemelli.it
+390630154965
Raffaella Chini, MD
Contact
raffaella.chini@guest.policlinicogemelli.it
+390630154965
Angela Rizzi, MD, PhD
principal investigator · Catholic University of Sacred Heart
Eleonora G Nucera, Prof., MD
principal investigator · Catholic University of Sacred Heart
Domenico Staiti, Prof., MD
principal investigator · Catholic University of Sacred Heart
Antonio Gasbarrini, Prof., MD
study director · Catholic University of Sacred Heart
Vincenzo Valentini, Prof., MD
study director · Catholic University of Sacred Heart

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion